TrimRx pulls ahead on medication variety, guarantee terms, and a cleaner regulatory record
The ongoing SELECT trial [10] will document the actual impact of semaglutide treatment on cardiovascular outcomes in high-risk adults and established CVD and without diabetes
Jensen, Bifen Luo, Guoyue Yuan, Guang Ning, for the PIONEER 11 investigators The prevalence of diabetes in China is estimated to increase over the coming decades, highlighting a clear treatment need
Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications
Think about the week ahead wherell you be at mealtimes and whatll youll eat
Gut Dysbiosis, intestinal permeability and constipation may increase endotoxin, microbial metabolites and enterohepatic recirculation